17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
17:04 - 
Tirsdagens aktier: Optimistiske forventninger løfter No..
11:44 - 
Aktier/middag: God købsmulighed i Novo Nordisk
09:28 - 
Aktier/åbning: Novo og Vestas sendes agterud i nervøst ..
Relateret debat
19:01 - 
Novo Seeds har også lige indgået en stor licensaftale....
16:44 - 
FDAs approval side er nede, så det er nok derfor,..
13:33 - 
tør man satse lidt på den her idag?  ..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
11:34
NOVO-B
Og du er sikkeer på at det er nordea der sælger ud og ikke deres kunder som handler gennem dem?
2
08:22
NOVO-B
Ser ikke ud til, at FDA har godkendt nogle nye produkter i går:   http://www.accessdata.fda.gov/scri..
1
17 okt
NOVO-B
Jeg har forstået at det fedmemiddel er lidt af et stunt. Der kræves at man følger en slankekur- elle..
1

Faldende oliepriser kan vende slow-steaming-trenden - medie

21-10-2014 13:05:42
De faldende bunkerpriser kan få rederierne til at ændre strategien med slow steaming og igen øge hastigheden, hvilket vil kunne spare omkostninger, specielt hvi..

Aktier/middag: God købsmulighed i Novo Nordisk

21-10-2014 11:44:51
Tirsdagen byder på mulighed for et godt køb i Novo-aktien, der ved middagstid noterer en blot marginal kursstigning på 0,04 pct. til 260,90 kr. i et ellers lyst..

Aktier/tendens: DSV og bankerne kan få hovedroller

21-10-2014 08:35:53
Det tegner til let bølgegang fra åbningen tirsdag, hvor DSV og bankerne kan komme i fokus efter nyt fra branchefæller. Swedbank er kommet med et stærkt regnskab..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: God købsmulighed i Novo Nordisk
2
Vestas opdater kinesisk strategi
3
Aktier/tendens: DSV og bankerne kan få hovedroller
4
Novo har ikke hørt fra FDA om fedmemedicin
5
Aktier/åbning: Novo og Vestas sendes agterud i nervøst marked

Relaterede aktiekurser

Novo Nordisk B A/S 263,70 1,1% Stigning i aktiekurs
Novo-Nordisk A/S 45,38 1,0% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. oktober 2014 21:59:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141015.1 - EUROWEB5 - 2014-10-21 21:59:06 - 2014-10-21 21:59:06 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x